Cited by 7,810Pancreatic and Hepatic Oncology ResearchPancreatitis Pathology and TreatmentCancer Treatment and Pharmacology

The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.

FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer

Open access

Conroy, Thierry, Desseigne, Françoise, Ychou, Marc, Bouché, Olivier, Guimbaud, Rosine, Bécouarn, Yves, Adenis, Antoine, Raoul, Jean-Luc, Gourgou-Bourgade, Sophie, de la Fouchardière, Christelle, Bennouna, Jaafar, Bachet, Jean-Baptiste, Khemissa-Akouz, Faiza, Péré-Vergé, Denis, Delbaldo, Catherine, Assenat, Eric, Chauffert, Bruno, Michel, Pierre, Montoto-Grillot, Christine, Ducreux, Michel·2011·New England Journal of Medicine

DOI 10.1056/nejmoa1011923

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: Data are lacking on the efficacy and safety of a combination chemotherapy regimen consisting of oxaliplatin, irinotecan, fluorouracil, and leucovorin (FOLFIRINOX) as compared with gemcitabine as first-line therapy in patients with metastatic pancreatic cancer. METHODS: We randomly assigned 342 patients with an Eastern Cooperative Oncology Group performance status score of 0 or 1 (on a scale of 0 to 5, with higher scores indicating a greater severity of illness) to receive FOLFIRINOX (oxaliplatin, 85 mg per square meter of body-surface area; irinotecan, 180 mg per square meter; leucovorin, 400 mg per square meter; and fluorouracil, 400 mg per square meter given as a bolus followed by 2400 mg per square meter given as a 46-hour continuous infusion, every 2 weeks) or gemcitabine at a dose of 1000 mg per square meter weekly for 7 of 8 weeks and then weekly for 3 of 4 weeks. Six months of chemotherapy were recommended in both groups in patients who had a response. The primary end point was overall survival. RESULTS: The median overall survival was 11.1 months in the FOLFIRINOX group as compared with 6.8 months in the gemcitabine group (hazard ratio for death, 0.57; 95% confidence interval [CI], 0.45 to 0.73; P<0.001). Median progression-free survival was 6.4 months in the FOLFIRINOX group and 3.3 months in the gemcitabine group (hazard ratio for disease progression, 0.47; 95% CI, 0.37 to 0.59; P<0.001). The objective response rate was 31.6% in the FOLFIRINOX group versus 9.4% in the gemcitabine group (P<0.001). More adverse events were noted in the FOLFIRINOX group; 5.4% of patients in this group had febrile neutropenia. At 6 months, 31% of the patients in the FOLFIRINOX group had a definitive degradation of the quality of life versus 66% in the gemcitabine group (hazard ratio, 0.47; 95% CI, 0.30 to 0.70; P<0.001). CONCLUSIONS: As compared with gemcitabine, FOLFIRINOX was associated with a survival advantage and had increased toxicity. FOLFIRINOX is an option for the treatment of patients with metastatic pancreatic cancer and good performance status. (Funded by the French government and others; ClinicalTrials.gov number, NCT00112658.).

Integrity signals

Registry

Crossref · 10.1056/nejmoa1011923

Cites

37 of 37 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer series in statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,239
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in Oncology
Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., Filiberti, A., Flechtner, H., Fleishman, S. B., Haes, J. C. J. M. D., et al. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.5.365 · Cited by 16,005
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Cancer Statistics, 2010
Jemal, A., Siegel, R., Xu, J., & Ward, E. (2010) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20073 · Cited by 12,596
Toxicity and response criteria of the Eastern Cooperative Oncology Group
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., Mcfadden, E. T., & Carbone, P. P. (1982) · American Journal of Clinical Oncology · doi:10.1097/00000421-198212000-00014 · Cited by 11,686
Pancreatic Cancer
Spencer, P. M., Cameron, J. L., & Lin, L. (2000) · Cited by 7,202
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Burris, H. A., Moore, M. J., Andersen, J., Green, M. R., Rothenberg, M. L., Modiano, M., Cripps, M. C., Portenoy, R. K., Storniolo, A. M., Tarassoff, P. G., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.6.2403 · Cited by 5,895
Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group
Moore, M. J., Goldstein, D., Hamm, J., Figer, A., Hecht, J. R., Gallinger, S., Au, H. J., Murawa, P., Walde, D., Wolff, R. A., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.9525 · Cited by 3,848
Interpreting the significance of changes in health-related quality-of-life scores.
Osoba, D., Rodrigues, G., Myles, J., Zee, B. C.-Y., & Pater, J. L. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.1.139 · Cited by 3,016

Flagged first, then by citations

Show all 37 references

Research works printed but not linked: 3

Zeghari-Squalli N, 1999, Clin Cancer Res, 5, 1189
10.2307/2281868 · DOI · Paper page
Introduction and methods. In: Early Breast Cancer Trialists' Collaborative Group. Treatment of early breast cancer. Vol. 1. Worldwide evidence 1985–1990. Oxford, England: Oxford University Press, 1990.

Sorted by citations

Items 701–800 of 1,032

A randomised phase II trial of the Polo-like kinase inhibitor BI 2536 in chemo-naïve patients with unresectable exocrine adenocarcinoma of the pancreas – a study within the Central European Society Anticancer Drug Research (CESAR) collaborative network
Mross, K. B., Dittrich, C., Aulitzky, W. E., Strumberg, D., Schütte, J., Schmid, R. M., Hollerbach, S., Merger, M., Munzert, G. M., Fleischer, F., et al. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.257 · Cited by 86
Eligibility of Metastatic Pancreatic Cancer Patients for First-Line Palliative Intent nab-Paclitaxel Plus Gemcitabine Versus FOLFIRINOX
Peixoto, R. D., Ho, M., Renouf, D. J., Lim, H. J., Gill, S., Ruan, J. Y., & Cheung, W. Y. (2015) · American Journal of Clinical Oncology · doi:10.1097/coc.0000000000000193 · Cited by 88
Overall survival and clinical characteristics of BRCA mutation carriers with stage I/II pancreatic cancer
Golan, T., Sella, T., O'Reilly, E. M., Katz, M. H. G., Epelbaum, R., Kelsen, D. P., Borgida, A., Maynard, H., Kindler, H. L., Friedmen, E., et al. (2017) · British Journal of Cancer · doi:10.1038/bjc.2017.19 · Cited by 86
Locally Advanced Unresectable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline Summary
Balaban, E. P., Mangu, P. B., & Yee, N. S. (2016) · Journal of Oncology Practice · doi:10.1200/jop.2016.017376 · Cited by 88
Digestive cancers: mechanisms, therapeutics and management
Zhan, T., Betge, J., Schulte, N., Dreikhausen, L., Hirth, M., Li, M., Weidner, P., Leipertz, A., Teufel, A., & Ebert, M. P. A. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02097-4 · Cited by 90
Early recurrence of pancreatic cancer after resection and during adjuvant chemotherapy
Breidert, M., Fischer, R., Keck, T., Makowiec, F., Lohrmann, C., & Harder, J. (2012) · Saudi Journal of Gastroenterology · doi:10.4103/1319-3767.93815 · Cited by 85
Pancreatic Adenocarcinoma Management
Jiang, Y., & Sohal, D. P. S. (2022) · JCO Oncology Practice · doi:10.1200/op.22.00328 · Cited by 94
Evaluation of Modified Glasgow Prognostic Score for Pancreatic Cancer
Imaoka, H., Mizuno, N., Hara, K., Hijioka, S., Tajika, M., Tanaka, T., Ishihara, M., Yogi, T., Tsutsumi, H., Fujiyoshi, T., et al. (2015) · Pancreas · doi:10.1097/mpa.0000000000000446 · Cited by 84
Recent advances in pancreatic cancer: biology, treatment, and prevention
Singh, D. K., Upadhyay, G., Srivastava, R. K., & Shankar, S. (2015) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2015.04.003 · Cited by 85
Tremelimumab: research and clinical development
Ibarrondo, F. J., Comin-Anduix, B., & Escuin-Ordinas, H. (2016) · OncoTargets and Therapy · doi:10.2147/ott.s65802 · Cited by 86
Pancreatic Cancer
Yabar, C. S., & Winter, J. M. (2016) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2016.04.003 · Cited by 85
Comparing the diagnostic accuracy of five common tumour biomarkers and CA19-9 for pancreatic cancer: a protocol for a network meta-analysis of diagnostic test accuracy
Ge, L., Pan, B., Song, F., Ma, J., Zeraatkar, D., Zhou, J., & Tian, J. (2017) · BMJ Open · doi:10.1136/bmjopen-2017-018175 · Cited by 87
Emerging Role of Immune Checkpoint Blockade in Pancreatic Cancer
Macherla, S., Laks, S., Naqash, A. R., Bulumulle, A., Zervos, E. E., & Muzaffar, M. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19113505 · Cited by 87
Metabolic Dependencies in Pancreatic Cancer
Gohar, A. V., Zarei, M., Brody, J. R., & Winter, J. M. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00617 · Cited by 87
Prognosis and survival analysis of patients with pancreatic cancer: retrospective experience of a single institution
Li, Q., Feng, Z., Miao, R., Liu, X., Liu, C., & Liu, Z. (2022) · World Journal of Surgical Oncology · doi:10.1186/s12957-021-02478-x · Cited by 86
The conflicting roles of tumor stroma in pancreatic cancer and their contribution to the failure of clinical trials: a systematic review and critical appraisal
Bijlsma, M. F., & van Laarhoven, H. W. M. (2015) · Cancer and Metastasis Reviews · doi:10.1007/s10555-014-9541-1 · Cited by 84
Pathologic Major Response After FOLFIRINOX is Prognostic for Patients Secondary Resected for Borderline or Locally Advanced Pancreatic Adenocarcinoma: An AGEO-FRENCH, Prospective, Multicentric Cohort
Pietrasz, D., Marthey, L., Wagner, M., Blanc, J., Laurent, C., Turrini, O., Raoul, J., Terrebonne, É., Hentic, O., Trouilloud, I., et al. (2015) · Annals of Surgical Oncology · doi:10.1245/s10434-015-4783-x · Cited by 84
Self-citation
Modest Improvement in Overall Survival for Patients With Metastatic Pancreatic Cancer
Worni, M., Güller, U., White, R. R., Castleberry, A. W., Pietrobon, R. S., Cerny, T., Gloor, B., & Koeberle, D. (2013) · Pancreas · doi:10.1097/mpa.0b013e318291fbc5 · Cited by 83
Overall survival is increased among stage III pancreatic adenocarcinoma patients receiving neoadjuvant chemotherapy compared to surgery first and adjuvant chemotherapy: An intention to treat analysis of the National Cancer Database
Shubert, C. R., Bergquist, J. R., Groeschl, R. T., Habermann, E. B., Wilson, P. M., Truty, M. J., Smoot, R. L., Kendrick, M. L., Nagorney, D. M., & Farnell, M. B. (2016) · Surgery · doi:10.1016/j.surg.2016.06.010 · Cited by 83
Emerging concepts in pancreatic cancer medicine: targeting the tumor stroma
Neeße, A., Gress, T. M., Tuveson, D. A., Michl, P., & Krug, S. (2013) · OncoTargets and Therapy · doi:10.2147/ott.s38111 · Cited by 87
High-intensity focused ultrasound (HIFU) for pancreatic carcinoma: evaluation of feasibility, reduction of tumour volume and pain intensity
Marinova, M., Rauch, M., Mücke, M., Rolke, R., Gonzalez-Carmona, M. A., Henseler, J., Cuhls, H., Radbruch, L., Strassburg, C. P., Zhang, L., et al. (2016) · European Radiology · doi:10.1007/s00330-016-4239-0 · Cited by 84
Chinese Medicine in Cancer Treatment – How is it Practised in the East and the West?
So, T. H., Chan, S.-K., Lee, V. H.-F., Chen, B., Kong, F., & Lao, L. (2019) · Clinical Oncology · doi:10.1016/j.clon.2019.05.016 · Cited by 84
A randomized phase II trial of nab‐paclitaxel and gemcitabine with tarextumab or placebo in patients with untreated metastatic pancreatic cancer
Hu, Z. I., Bendell, J. C., Bullock, A., LoConte, N. K., Hatoum, H., Ritch, P., Hool, H., Leach, J. W., Sanchez, J., Sohal, D. P. S., et al. (2019) · Cancer Medicine · doi:10.1002/cam4.2425 · Cited by 82
Targeted Therapies for Pancreatic Cancer
Amanam, I. U., & Chung, V. M. (2018) · Cancers · doi:10.3390/cancers10020036 · Cited by 85
Pancreatic cancer survival analysis defines a signature that predicts outcome
Raman, P., Maddipati, R., Lim, K., & Tözeren, A. (2018) · PLoS ONE · doi:10.1371/journal.pone.0201751 · Cited by 84
Comparative Effectiveness of nab-Paclitaxel Plus Gemcitabine vs FOLFIRINOX in Metastatic Pancreatic Cancer: A Retrospective Nationwide Chart Review in the United States
Kim, S. S. Y., Signorovitch, J., Yang, H., Patterson‐Lomba, O., Xiang, C. Q., Ung, B. L., Parisi, M., & Marshall, J. L. (2018) · Advances in Therapy · doi:10.1007/s12325-018-0784-z · Cited by 83
Thermal ablation of pancreatic cancer: A systematic literature review of clinical practice and pre-clinical studies
Saccomandi, P., Lapergola, A., Longo, F., Schena, E., & Quero, G. (2018) · International Journal of Hyperthermia · doi:10.1080/02656736.2018.1506165 · Cited by 82
The Paradoxical Web of Pancreatic Cancer Tumor Microenvironment
Lafaro, K. J., & Melstrom, L. G. (2018) · American Journal Of Pathology · doi:10.1016/j.ajpath.2018.09.009 · Cited by 87
Circulating Tumor Cells in Pancreatic Cancer: Current Perspectives
Martini, V., Timme‐Bronsert, S., Fichtner‐Feigl, S., Hoeppner, J., & Kulemann, B. (2019) · Cancers · doi:10.3390/cancers11111659 · Cited by 83
Assessing the efficacy‐effectiveness gap for cancer therapies: A comparison of overall survival and toxicity between clinical trial and population‐based, real‐world data for contemporary parenteral cancer therapeutics
Phillips, C. M., Parmar, A., Guo, H., Schwartz, D., Isaranuwatchai, W., Beca, J. M., Dai, W. F., Arias, J., Gavura, S., & Chan, K. (2020) · Cancer · doi:10.1002/cncr.32697 · Cited by 85
En Bloc Celiac Axis Resection for Pancreatic Cancer: Classification of Anatomical Variants Based on Tumor Extent
Truty, M. J., Colglazier, J. J., Mendes, B. C., Nagorney, D. M., Bower, T. C., Smoot, R. L., DeMartino, R. R., Cleary, S. P., Oderich, G. S., & Kendrick, M. L. (2020) · Journal of the American College of Surgeons · doi:10.1016/j.jamcollsurg.2020.05.005 · Cited by 84
First line Immunotherapy for Non-Small Cell Lung Cancer
Nasser, N. J., Gorenberg, M., & Agbarya, A. (2020) · Pharmaceuticals · doi:10.3390/ph13110373 · Cited by 83
Oncological Outcome of Conversion Surgery After Preoperative Chemotherapy for Metastatic Pancreatic Cancer
Hank, T. P., Klaiber, U., Hinz, U., Schütte, D., Leonhardt, C.-S., Bergmann, F., Hackert, T., Jäger, D., Büchler, M. W., & Strobel, O. (2022) · Annals of Surgery · doi:10.1097/sla.0000000000005481 · Cited by 83
New strategies and designs in pancreatic cancer research: consensus guidelines report from a European expert panel
Laethem, J. V., Verslype, C., Iovanna, J., Michl, P., Conroy, T., Louvet, C., Hammel, P. R., Mitry, E., Ducreux, M. P., Maraculla, T., et al. (2011) · Annals of Oncology · doi:10.1093/annonc/mdr351 · Cited by 82
Self-citation
Asparagine Synthetase Expression and Phase I Study With L-Asparaginase Encapsulated in Red Blood Cells in Patients With Pancreatic Adenocarcinoma
Bachet, J., Gay, F., Maréchal, R., Galais, M., Adenis, A., Salako, D., Cros, J. F., Demetter, P., Svrcek, M., Bardier–Dupas, A., et al. (2015) · Pancreas · doi:10.1097/mpa.0000000000000394 · Cited by 83
Self-citation
Ginkgolic acid suppresses the development of pancreatic cancer by inhibiting pathways driving lipogenesis
Ma, J., Duan, W., Han, S., Lei, J., Xu, Q., Chen, X., Jiang, Z., Nan, L., Li, J., Chen, K., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.3663 · Cited by 81
Biomarkers and Targeted Therapy in Pancreatic Cancer
Karandish, F., & Mallik, S. (2016) · Biomarkers in Cancer · doi:10.4137/bic.s34414 · Cited by 82
Aptamer-Drug Conjugates of Active Metabolites of Nucleoside Analogs and Cytotoxic Agents Inhibit Pancreatic Tumor Cell Growth
Yoon, S., Huang, K., Reebye, V., Spalding, D. R. C., Przytycka, T. M., Wang, Y., Swiderski, P. M., Li, L., Armstrong, B., Reccia, I., et al. (2016) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2016.11.008 · Cited by 81
Tumor size classification of the 8th edition of TNM staging system is superior to that of the 7th edition in predicting the survival outcome of pancreatic cancer patients after radical resection and adjuvant chemotherapy
Cong, L., Liu, Q., Zhang, R., Cui, M., Zhang, X., Gao, X., Guo, J., Dai, M., Zhang, T., Liao, Q., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-28193-4 · Cited by 91
RNA Polymerase II-Associated Factor 1 Regulates Stem Cell Features of Pancreatic Cancer Cells, Independently of the PAF1 Complex, via Interactions With PHF5A and DDX3
Karmakar, S., Rauth, S., Nallasamy, P., Perumal, N., Nimmakayala, R. K., Leon, F., Gupta, R., Barkeer, S., Venkata, R. C., Raman, V., et al. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.07.053 · Cited by 81
Implication of PI3K/Akt pathway in pancreatic cancer: When PI3K isoforms matter?
Baer, R., Cintas, C., Therville, N., & Guillermet‐Guibert, J. (2015) · Advances in Biological Regulation · doi:10.1016/j.jbior.2015.05.001 · Cited by 85
An in vitro and in vivo study of gemcitabine-loaded albumin nanoparticles in a pancreatic cancer cell line
Yu, X., Pu, X., Xie, C. L., Song, Y., He, H., Li, H., Lu, W., Fu, D., Jin, C., & Yang, D. (2015) · International Journal of Nanomedicine · doi:10.2147/ijn.s93835 · Cited by 83
Tissue factor-bearing microparticles and CA19.9: two players in pancreatic cancer-associated thrombosis?
Woei-A-Jin, F. J. S. H., Tesselaar, M. E. T., Rodriguez, P. G., Romijn, F. P. H. T. M., Bertina, R. M., & Osanto, S. (2016) · British Journal of Cancer · doi:10.1038/bjc.2016.170 · Cited by 81
Activation of protein phosphatase 2A tumor suppressor as potential treatment of pancreatic cancer
Chien, W., Sun, Q.-Y., Lee, K. L., Ding, L.-W., Wuensche, P., Torres-Fernandez, L. A., Tan, S. Z., Tokatly, I., Zaiden, N., Poellinger, L., et al. (2015) · Molecular Oncology · doi:10.1016/j.molonc.2015.01.002 · Cited by 80
Full dose neoadjuvant FOLFIRINOX is associated with prolonged survival in patients with locally advanced pancreatic adenocarcinoma
Khushman, M. M., Dempsey, N. G., Maldonado, J. C., Loaiza‐Bonilla, A., Velez, M., Carcas, L., Dammrich, D., Hurtado-Cordovi, J. M., Parajuli, R., Pollack, T., et al. (2015) · Pancreatology · doi:10.1016/j.pan.2015.08.010 · Cited by 81
Immunotherapy in pancreatic cancer treatment: a new frontier
Thind, K., Padrnos, L. J., Ramanathan, R. K., & Borad, M. J. (2016) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756283x16667909 · Cited by 83
Induction chemotherapy in pancreatic cancer: CA 19-9 may predict resectability and survival
Heger, U., Sun, H.-H., Hinz, U., Klaiber, U., Tanaka, M., Liu, B., Sachsenmaier, M., Springfeld, C., Michalski, C. W., Büchler, M. W., et al. (2019) · HPB · doi:10.1016/j.hpb.2019.06.012 · Cited by 80
Redox-responsive nanoplatform for codelivery of miR-519c and gemcitabine for pancreatic cancer therapy
Xin, X., Kumar, V., Lin, F., Kumar, V., Bhattarai, R. S., Bhatt, V. R., Tan, C., & Mahato, R. I. (2020) · Science Advances · doi:10.1126/sciadv.abd6764 · Cited by 80
First-In-Human Phase I Study of a Next-Generation, Oral, TGFβ Receptor 1 Inhibitor, LY3200882, in Patients with Advanced Cancer
Yap, T. A., Vieito, M., Baldini, C., Sepúlveda-Sánchez, J. M., Kondo, S., Simonelli, M., Cosman, R., van der Westhuizen, A., Atkinson, V. G., Carpentier, A. F., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-1504 · Cited by 83
Pancreatic cancer: Role of the immune system in cancer progression and vaccine-based immunotherapy
Amedei, A., Niccolai, E., & Prisco, D. (2014) · Human Vaccines & Immunotherapeutics · doi:10.4161/hv.34392 · Cited by 80
Genetic Events That Limit the Efficacy of MEK and RTK Inhibitor Therapies in a Mouse Model of KRAS-Driven Pancreatic Cancer
Pettazzoni, P., Viale, A., Shah, P. K., Carugo, A., Ying, H., Wang, H., Genovese, G., Seth, S., Minelli, R., Green, T., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-1854 · Cited by 83
Systematic review of irreversible electroporation in the treatment of advanced pancreatic cancer
Moir, J., White, S., French, J., Littler, P., & Manas, D. (2014) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2014.08.480 · Cited by 80
Clinically Meaningful Use of Blood Tumor Markers in Oncology
Holdenrieder, S., Pagliaro, L. C., Morgenstern, D. E., & Dayyani, F. (2016) · BioMed Research International · doi:10.1155/2016/9795269 · Cited by 84
Inhibition of ROCK1 kinase modulates both tumor cells and stromal fibroblasts in pancreatic cancer
Whatcott, C. J., Ng, S., Barrett, M. T., Hostetter, G. H., Hoff, D. D. V., & Han, H. (2017) · PLoS ONE · doi:10.1371/journal.pone.0183871 · Cited by 81
iRGD-guided Tumor-penetrating Nanocomplexes for Therapeutic siRNA Delivery to Pancreatic Cancer
Lo, J. H.-J., Hao, L., Muzumdar, M. D., Raghavan, S., Kwon, E. J., Pulver, E. M., Hsu, F., Aguirre, A. J., Wolpin, B. M., Fuchs, C. S., et al. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-1090 · Cited by 80
Resection versus other treatments for locally advanced pancreatic cancer
Gurusamy, K. S., Kumar, S., V, Davidson, B. R., & Fusai, G. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010244.pub2 · Cited by 79
Overcoming nucleoside analog chemoresistance of pancreatic cancer: A therapeutic challenge
Hung, S. W., Mody, H. R., & Govindarajan, R. (2012) · Cancer Letters · doi:10.1016/j.canlet.2012.03.007 · Cited by 79
Germline and Somatic DNA Damage Repair Gene Mutations and Overall Survival in Metastatic Pancreatic Adenocarcinoma Patients Treated with FOLFIRINOX
Sehdev, A., Gbolahan, O. B., Hancock, B. A., Stanley, M., Shahda, S., Wan, J., Wu, H. H., Radovich, M., & O’Neil, B. H. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1472 · Cited by 82
Ursolic acid promotes apoptosis, autophagy, and chemosensitivity in gemcitabine‐resistant human pancreatic cancer cells
Lin, J., Chen, S., Lu, C., Lin, J., & Yen, G. (2020) · Phytotherapy Research · doi:10.1002/ptr.6669 · Cited by 79
A Neoantigen-Based Peptide Vaccine for Patients With Advanced Pancreatic Cancer Refractory to Standard Treatment
Chen, Z., Zhang, S., Han, N., Jiang, J., Xu, Y., Ma, D., Lu, L., Guo, X., Qiu, M. R., Huang, Q., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.691605 · Cited by 79
Combination cancer immunotherapy targeting TNFR2 and PD-1/PD-L1 signaling reduces immunosuppressive effects in the microenvironment of pancreatic tumors
Zhang, X., Lao, M., Xu, J., Duan, Y., Yang, H., Li, M., Ying, H., He, L., Sun, K., Guo, C., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003982 · Cited by 83
Iron-Sensitive Prodrugs That Trigger Active Ferroptosis in Drug-Tolerant Pancreatic Cancer Cells
Antoszczak, M., Müller, S., Cañeque, T., Colombeau, L., Dusetti, N., Santofimia‐Castaño, P., Gaillet, C., Puisieux, A., Iovanna, J., & Rodriguez, R. (2022) · Journal of the American Chemical Society · doi:10.1021/jacs.2c03973 · Cited by 80
A bioinformatics analysis, pre-clinical and clinical conception of autophagy in pancreatic cancer: Complexity and simplicity in crosstalk
Ashrafizadeh, M., Zhang, W., Zou, R., Sethi, G., Klionsky, D. J., & Zhang, X. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106822 · Cited by 79
Metabolic classification suggests the GLUT1/ALDOB/G6PD axis as a therapeutic target in chemotherapy-resistant pancreatic cancer
Li, Y., Tang, S., Shi, X., Lv, J., Wu, X., Zhang, Y., Wang, H., He, J., Zhu, Y., Ju, Y., et al. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.101162 · Cited by 79
Plac8 Links Oncogenic Mutations to Regulation of Autophagy and Is Critical to Pancreatic Cancer Progression
Kinsey, C. G., Balakrishnan, V., O’Dell, M. R., Huang, J. L., Newman, L. A., Whitney‐Miller, C. L., Hezel, A. F., & Land, H. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.03.061 · Cited by 81
Postoperative prognosis of pancreatic cancer with para-aortic lymph node metastasis: a multicenter study on 822 patients
Sho, M., Murakami, Y., Motoi, F., Satoi, S., Matsumoto, I., Kawai, M., Honda, G., Uemura, K., Yanagimoto, H., Kurata, M., et al. (2014) · Journal of Gastroenterology · doi:10.1007/s00535-014-1005-4 · Cited by 79
Statistical controversies in clinical research: end points other than overall survival are vital for regulatory approval of anticancer agents
Saad, E. D., & Buyse, M. E. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv562 · Cited by 81
Targeting Cancer Stem Cells for Chemoprevention of Pancreatic Cancer
Subramaniam, D., Kaushik, G., Dandawate, P. R., & Anant, S. (2017) · Current Medicinal Chemistry · doi:10.2174/0929867324666170127095832 · Cited by 80
Systemic Chemotherapy Combined with Resection for Locally Advanced Gallbladder Carcinoma: Surgical and Survival Outcomes
Creasy, J. M., Goldman, D. A., Dudeja, V., Lowery, M. A., Cercek, A., Balachandran, V. P., Allen, P. J., DeMatteo, R. P., Kingham, T. P., D'Angelica, M. I., et al. (2017) · Journal of the American College of Surgeons · doi:10.1016/j.jamcollsurg.2016.12.058 · Cited by 79
Therapeutic Advances in Localized Pancreatic Cancer
Tsai, S., & Evans, D. B. (2016) · JAMA Surgery · doi:10.1001/jamasurg.2016.1113 · Cited by 78
Current and future biomarkers for pancreatic adenocarcinoma
Loosen, S. H., Neumann, U. P., Trautwein, C., Roderburg, C., & Luedde, T. (2017) · Tumor Biology · doi:10.1177/1010428317692231 · Cited by 81
Floxuridine Homomeric Oligonucleotides “Hitchhike” with Albumin In Situ for Cancer Chemotherapy
Jin, C. Y., Zhang, H., Zou, J., Liu, Y., Zhang, L., Li, F., Wang, R., Xuan, W., Ye, M., & Tan, W. (2018) · Angewandte Chemie International Edition · doi:10.1002/anie.201804156 · Cited by 78
Organoid models for translational pancreatic cancer research
Tiriac, H., Plenker, D., Baker, L. A., & Tuveson, D. A. (2019) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2019.02.003 · Cited by 81
A systemic inflammation response index (SIRI) correlates with survival and predicts oncological outcome for mFOLFIRINOX therapy in metastatic pancreatic cancer
Pacheco-Barcía, V., Solís, R. M., France, T., Asselah, J., Donnay, O., Zogopoulos, G., Bouganim, N., Guo, K., Rogado, J., Martín, E., et al. (2019) · Pancreatology · doi:10.1016/j.pan.2019.12.010 · Cited by 79
Phase Ib Study of Wnt Inhibitor Ipafricept with Gemcitabine and nab-paclitaxel in Patients with Previously Untreated Stage IV Pancreatic Cancer
Dotan, E., Cardin, D. B., Lenz, H., Messersmith, W. A., O’Neil, B. H., Cohen, S. J., Denlinger, C. S., Shahda, S., Astsaturov, I. A., Kapoun, A. M., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-0489 · Cited by 78
Molecular mediators of peritoneal metastasis in pancreatic cancer
Avula, L. R., Hagerty, B. L., & Alewine, C. (2020) · Cancer and Metastasis Reviews · doi:10.1007/s10555-020-09924-4 · Cited by 79
LAMC2 promotes cancer progression and gemcitabine resistance through modulation of EMT and ATP-binding cassette transporters in pancreatic ductal adenocarcinoma
Okada, Y., Takahashi, N., Takayama, T., & Goel, A. (2021) · Carcinogenesis · doi:10.1093/carcin/bgab011 · Cited by 80
Clinical Impact of Molecular Subtyping of Pancreatic Cancer
Zhou, X., Hu, K., Bailey, P. J., Springfeld, C., Roth, S., Kurilov, R., Brors, B., Gress, T. M., Buchholz, M., An, J., et al. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.743908 · Cited by 84
The Immune Landscape of Human Pancreatic Ductal Carcinoma: Key Players, Clinical Implications, and Challenges
Müller, M., Haghnejad, V., Schaefer, M., Gauchotte, G., Caron, B., Peyrin‐Biroulet, L., Bronowicki, J., Neuzillet, C., & Lopez, A. (2022) · Cancers · doi:10.3390/cancers14040995 · Cited by 83
CD73 Inhibits cGAS–STING and Cooperates with CD39 to Promote Pancreatic Cancer
Jacoberger-Foissac, C., Cousineau, I., Barèche, Y., Allard, D., Chrobák, P., Allard, B., Pommey, S., Messaoudi, N., McNicoll, Y., Soucy, G., et al. (2022) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-22-0260 · Cited by 78
Feline exocrine pancreatic carcinoma: a retrospective study of 34 cases
Linderman, M. J., Brodsky, E. M., Lorimier, L. P. D., Clifford, C. A., & Post, G. S. (2012) · Veterinary and Comparative Oncology · doi:10.1111/j.1476-5829.2012.00320.x · Cited by 78
Oncolytic adenovirus expressing relaxin (YDC002) enhances therapeutic efficacy of gemcitabine against pancreatic cancer
Jung, K. H., Choi, I.-K., Lee, H., YAN, H. H., Son, M. K., Ahn, H. M., Hong, J., Yun, C., & Hong, S. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.03.009 · Cited by 78
A phase 1/1B trial of ADI‐PEG 20 plus nab‐paclitaxel and gemcitabine in patients with advanced pancreatic adenocarcinoma
Lowery, M. A., Yu, K. H., Kelsen, D. P., Harding, J. J., Bomalaski, J. S., Glassman, D. C., Covington, C. M., Brenner, R., Hollywood, E. M., Barba, A., et al. (2017) · Cancer · doi:10.1002/cncr.30897 · Cited by 79
Precision medicine in cholangiocarcinoma
Pellino, A., Loupakis, F., Cadamuro, M., Dadduzio, V., Fassan, M., Guido, M., Cillo, U., Indraccolo, S., & Fabris, L. (2018) · Translational Gastroenterology and Hepatology · doi:10.21037/tgh.2018.07.02 · Cited by 79
Failure Patterns in Resected Pancreas Adenocarcinoma
Winter, J. M., Tang, L. H., Klimstra, D. S., Liu, W., Linkov, I., Brennan, M. F., D'Angelica, M. I., DeMatteo, R. P., Fong, Y., Jarnagin, W. R., et al. (2013) · Annals of Surgery · doi:10.1097/sla.0b013e31827fe9ce · Cited by 77
Smarter drugs emerging in pancreatic cancer therapy
Kleger, A., Perkhofer, L., & Seufferlein, T. T. W. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu013 · Cited by 78
A prospective, multi-institution assessment of irreversible electroporation for treatment of locally advanced pancreatic adenocarcinoma: initial outcomes from the AHPBA pancreatic registry
Holland, M. M., Bhutiani, N., Kruse, E., Weiss, M. J., Christein, J. D., White, R. R., Huang, K., & Martin, R. C. G. (2019) · HPB · doi:10.1016/j.hpb.2018.12.004 · Cited by 77
Modulation of redox metabolism negates cancer-associated fibroblasts-induced treatment resistance in a heterotypic 3D culture platform of pancreatic cancer
Broekgaarden, M., Anbil, S. R., Bulin, A., Obaid, G., Mai, Z., Baglo, Y., Rizvi, I., & Hasan, T. G. (2019) · Biomaterials · doi:10.1016/j.biomaterials.2019.119421 · Cited by 78
Unsupervised class discovery in pancreatic ductal adenocarcinoma reveals cell-intrinsic mesenchymal features and high concordance between existing classification systems
Dijk, F., Veenstra, V. L., Soer, E. C., Dings, M. P. G., Zhao, L., Halfwerk, J. B. G., Hooijer, G. K. J., Damhofer, H., Marzano, M., Steins, A., et al. (2020) · Scientific Reports · doi:10.1038/s41598-019-56826-9 · Cited by 77
Clinical significance of skeletal muscle density and sarcopenia in patients with pancreatic cancer undergoing first-line chemotherapy: a retrospective observational study
Kim, I.-H., Choi, M. H., Lee, I. S., Hong, T. H., & Lee, M. A. (2021) · BMC Cancer · doi:10.1186/s12885-020-07753-w · Cited by 77
Opportunities and delusions regarding drug delivery targeting pancreatic cancer-associated fibroblasts
Liu, H., Shi, Y., & Qian, F. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.02.012 · Cited by 78
Nanoparticle-based therapeutic strategies targeting major clinical challenges in pancreatic cancer treatment
Tarannum, M., & Vivero-Escoto, J. L. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114357 · Cited by 77
Exploiting pancreatic cancer metabolism: challenges and opportunities
Santis, M. C. D., Bockorny, B., Hirsch, E., Cappello, P., & Martini, M. (2024) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2024.03.008 · Cited by 85
The rational design of a gemcitabine prodrug with AIE-based intracellular light-up characteristics for selective suppression of pancreatic cancer cells
Han, H., Jin, Q., Wang, Y., Chen, Y., & Ji, J. (2015) · Chemical Communications · doi:10.1039/c5cc06654a · Cited by 77
Genistein potentiates the antitumor effect of 5-Fluorouracil by inducing apoptosis and autophagy in human pancreatic cancer cells.
Suzuki, R., Kang, Y., Li, X., Roife, D., Zhang, R., & Fleming, J. B. (2014) · PubMed · Cited by 77
Risk factors for covered metallic stent migration in patients with distal malignant biliary obstruction due to pancreatic cancer
Nakai, Y., Isayama, H., Kogure, H., Hamada, T., Togawa, O., Ito, Y., Matsubara, S., Arizumi, T., Yagioka, H., Mizuno, S., et al. (2014) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.12602 · Cited by 77
YAP Inhibition by Resveratrol via Activation of AMPK Enhances the Sensitivity of Pancreatic Cancer Cells to Gemcitabine
Jiang, Z., Chen, X., Chen, K., Sun, L., Gao, L., Zhou, C., Meng, L., Duan, W., Wang, Z., Ma, Q., et al. (2016) · Nutrients · doi:10.3390/nu8100546 · Cited by 77
A phase II study to evaluate LY2603618 in combination with gemcitabine in pancreatic cancer patients
Laquente, B., Lopez-Martin, J. A., Richards, D., Illerhaus, G., Chang, D. Z., Kim, G., Stella, P. J., Richel, D. J., Szcylik, C., Cascinu, S., et al. (2017) · BMC Cancer · doi:10.1186/s12885-017-3131-x · Cited by 80
Clinical impact of circulating tumor cells and therapy response in pancreatic cancer
Okubo, K., Uenosono, Y., Arigami, T., Mataki, Y., Matsushita, D., Yanagita, S., Kurahara, H., Sakoda, M., Kijima, Y., Maemura, K., et al. (2017) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2017.01.241 · Cited by 77
Olaparib in combination with irinotecan, cisplatin, and mitomycin C in patients with advanced pancreatic cancer
Yarchoan, M. M., Myzak, M. C., Johnson, B. A., Jesus‐Acosta, A. D., Le, D. T., Jaffee, E. M., Azad, N. S., Donehower, R. C., Zheng, L., Oberstein, P. E., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.17237 · Cited by 78

Authors: Conroy, T., Desseigne, F., Ychou, M., Bouché, O., Guimbaud, R., Bécouarn, Y., Adenis, A., Raoul, J.-L., Gourgou-Bourgade, S., de la Fouchardière, C., Bennouna, J., Bachet, J.-B., Khemissa-Akouz, F., Péré-Vergé, D., Delbaldo, C., Assenat, E., Chauffert, B., Michel, P., Montoto-Grillot, C., & Ducreux, M.
Affiliations: Centre Léon Bérard (FR)
Centre Hospitalier Universitaire de Reims (FR)
Institut Claudius Regaud (FR)
Institut Bergonié (FR)
Centre Oscar Lambret (FR)
Centre Eugène Marquis (FR)
Hôpital Ambroise-Paré (FR)
Centre Hospitalier de Perpignan (FR)
Hôpital de la Croix-Rousse (FR)
Centre Hospitalier Universitaire Henri-Mondor (FR)
Centre Georges François Leclerc (FR)
Université de Rouen Normandie (FR)
UniCancer Group (FR)
Institut Gustave Roussy (FR)
ORCID: Conroy, Thierry
Ychou, Marc
Bouché, Olivier
Guimbaud, Rosine
Adenis, Antoine
Raoul, Jean-Luc
Bennouna, Jaafar
Bachet, Jean-Baptiste
Khemissa-Akouz, Faiza
Michel, Pierre
Montoto-Grillot, Christine
Ducreux, Michel
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2011-05-12
Volume: 364
Issue: 19
Pages: 1817-1825
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmoa1011923
OpenAlex: W2151253787
Cited by: 7,810
References: 37
Citations by year: 2026: 425 · 2025: 521 · 2024: 560 · 2023: 604 · 2022: 622 · 2021: 785 · 2020: 692 · 2019: 563 · 2018: 577 · 2017: 558 · 2016: 454 · 2015: 473 · 2014: 388 · 2013: 282 · 2012: 222
FWCI: 150.63
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
HAL (submittedVersion)
Topics: Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
Health Sciences › Medicine › Surgery › Pancreatitis Pathology and Treatment
Health Sciences › Medicine › Oncology › Cancer Treatment and Pharmacology
Keywords: FOLFIRINOX, gemcitabine, metastatic pancreatic cancer, first-line chemotherapy, oxaliplatin, irinotecan, 5-fluorouracil, leucovorin, overall survival, progression-free survival, objective response rate, febrile neutropenia, quality of life, adverse events, combination chemotherapy, randomized trial comparison
MeSH terms: Irinotecan, Oxaliplatin, Gemcitabine, Adenocarcinoma, Adult, Aged, Antimetabolites, Antineoplastic, Antineoplastic Combined Chemotherapy Protocols, Camptothecin, Leucovorin, Deoxycytidine, Female, Fluorouracil, Follow-Up Studies, Humans, Male, Middle Aged, Neoplasm Metastasis, Organoplatinum Compounds, Pancreatic Neoplasms, Quality of Life, Severity of Illness Index, Proportional Hazards Models, Survival Analysis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks